The findings could potentially lead to early adoption of a clinical algorithm to treat gallbladder cancer patients under neo‐adjuvant or adjuvant settings similar to the one commonly used for anti‐EGFR treatment in colorectal cancer. This evidence concerns the gene EGFR and gallbladder cancer.